Work Group Considerations: Proposed Recommendation Text for Policy Options

Mary Choi, MD, MPH
Viral Special Pathogens Branch
Centers for Disease Control and Prevention

Advisory Committee on Immunization Practices

February 26, 2020
1st Vaccination Policy Issue for Consideration Today

Vaccination of healthy, non-pregnant, non-lactating adults ≥ 18 years of age

Should pre-exposure vaccination with the rVSVΔG-ZEBOV-GP vaccine be recommended for individuals in the U.S. population responding to an outbreak of Ebola virus disease due to Ebola virus (species Zaire ebolavirus)?
1st Vaccination Policy Issue for Consideration Today

Vaccination of healthy, non-pregnant, non-lactating adults ≥ 18 years of age

Should pre-exposure vaccination with the rVSVDAG-ZEBOV-GP vaccine be recommended for individuals in the U.S. population responding to an outbreak of Ebola virus disease due to Ebola virus (species Zaire ebolavirus)?

WG proposal by strong majority: Recommend
Reasoning for “Recommend” Proposal: Individuals responding to an outbreak of EVD

- Documented history of infections in outbreak responders
- Benefits of vaccination outweigh the risk
  - Severe disease
  - No FDA-approved treatment
- Risk of exposure even with appropriate use of personal protective equipment
Pre-exposure vaccination with rVSVΔG-ZEBOV-GP vaccine is recommended for healthy, non-pregnant, non-lactating adults 18 years of age or older in the U.S. population who are responding to an outbreak of Ebola virus disease and are at potential risk for exposure to Ebola virus (species Zaire ebolavirus)
2nd Vaccination Policy Issue for Consideration Today

Vaccination of healthy, non-pregnant, non-lactating adults ≥ 18 years of age

Should pre-exposure vaccination with the rVSVΔG-ZEBOV-GP vaccine be recommended for healthcare personnel* involved in the care and transport of confirmed Ebola virus disease patients at federally-designated Ebola Treatment Centers in the United States?
Vaccination of healthy, non-pregnant, non-lactating adults ≥ 18 years of age

Should pre-exposure vaccination with the rVSVΔG-ZEBOV-GP vaccine be recommended for healthcare personnel* involved in the care and transport of confirmed Ebola virus disease patients at federally-designated Ebola Treatment Centers in the United States?

WG proposal by strong majority: Recommend
Reasoning for “Recommend” Proposal: HCP* at U.S. Federally-Designated Ebola Treatment Centers

- Operational ETCs with trained and vaccinated personnel is a part of public health preparedness
- Population is at high-risk of occupational exposure to the virus
- Provides an added layer of protection, in additional to other biosafety measures (e.g., personal protective equipment, engineering controls etc.)
Pre-exposure vaccination with rVSVΔG-ZEBOV-GP vaccine is recommended for healthy, non-pregnant, non-lactating adults 18 years of age or older who work as healthcare personnel\(^1\) at a federally-designated Ebola Treatment Center in the United States who are at potential risk for exposure to Ebola virus (species *Zaire ebolavirus*)
3\textsuperscript{nd} Vaccination Policy Issue for Consideration Today

Vaccination of healthy, non-pregnant, non-lactating adults $\geq$ 18 years of age

Should pre-exposure vaccination with the rVSVΔG-ZEBOV-GP vaccine be recommended for laboratorians and support staff at biosafety-level 4 facilities that handle replication-competent Ebola virus (species \textit{Zaire ebolavirus}) in the United States
3\textsuperscript{nd} Vaccination Policy Issue for Consideration Today

Vaccination of healthy, non-pregnant, non-lactating adults ≥ 18 years of age

Should pre-exposure vaccination with the rVSVΔG-ZEBOV-GP vaccine be recommended for laboratorians and support staff at biosafety-level 4 facilities that handle replication-competent Ebola virus (species Zaire ebolavirus) in the United States

WG proposal by strong majority : Recommend
Reasoning for “Recommend”: BSL-4 Laboratorians and Support Staff

- Population at high risk for occupational exposure
- Provides an added layer of protection, in additional to other biosafety measures (e.g., personal protective equipment, engineering controls etc.)
Pre-exposure vaccination with rVSVΔG-ZEBOV-GP vaccine is recommended for healthy, non-pregnant, non-lactating adults 18 years of age or older who work as laboratorians and support staff at biosafety-level 4 facilities in the U.S. who are at potential risk for exposure to Ebola virus (species *Zaire ebolavirus*)
Healthcare Personnel Definition

1. Healthcare personnel (HCP) refers to all paid and unpaid persons serving in healthcare settings who have the potential for direct or indirect exposure to patients or infectious materials, including body substances (e.g., blood, tissue, and specific body fluids); contaminated medical supplies, devices, and equipment; contaminated environmental surfaces; or contaminated air. These HCP include, but are not limited to, emergency medical service personnel, nurses, nursing assistants, physicians, technicians, clinical laboratory personnel, autopsy personnel, therapists, phlebotomists, pharmacists, students and trainees, contractual staff not employed by the healthcare facility, and persons not directly involved in patient care, but who could be exposed to infectious agents that can be transmitted in the healthcare setting (e.g., clerical, dietary, environmental services, laundry, security, engineering and facilities management, administrative, billing, and volunteer personnel).

Adapted from https://www.cdc.gov/infectioncontrol/guidelines/healthcare-personnel/index.html
Ebola Vaccine ACIP Work Group

ACIP Members
Sharon Frey (Chair)
Beth Bell
Robert Atmar

Ex Officio Members
Rebecca Reindel (FDA)
Stephanie Polo (FDA)
Eric Deussing (DOD)
Amanda Zarrabian (BARDA)
Dan Wolfe (BARDA)
Elizabeth Higgs (NIH)
Richard Davey (NIH)
John Redd (ASPR)

Liaison Representatives
Alexander Isakov (ACEP)
Laura Riley (ACOG)
Sandra Adamson Fryhofer (AMA)
Christine Hahn (CSTE)
Milan Patel (NACI)
Chris Nyquist (AAP)
Daniel Lucey (IDSA)
David Weber (SHEA)

Consultants
Colleen Kraft (Emory University)
Jim LeDuc (UTMB)
Pierre Rollin
Allison Liddell (Texas Health Dallas)
Armand Sprecher (MSF)
Stacy Hall (AIM)
# Grade Consultants/CDC Contributors

<table>
<thead>
<tr>
<th>GRADE Consultants</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Rebecca Morgan</td>
<td>Susan Goldstein</td>
</tr>
<tr>
<td>Doug Campos-Outcalt</td>
<td>Inger Damon</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CDC Contributors</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Caitlin Cossaboom</td>
<td>Susan Gorman</td>
</tr>
<tr>
<td>Amy Whitesell</td>
<td>Michael Bell</td>
</tr>
<tr>
<td>Jonathan Dyal</td>
<td>Shah Roohi</td>
</tr>
<tr>
<td>Allison Joyce</td>
<td>Julianne Gee</td>
</tr>
<tr>
<td>Susan Gorman</td>
<td>Jennifer McQuiston</td>
</tr>
<tr>
<td>Jessica MacNeil</td>
<td>Elizabeth Ervin</td>
</tr>
<tr>
<td>Sarah Mbaeyi</td>
<td>John Su</td>
</tr>
<tr>
<td>Marissa Person</td>
<td>Joel Montgomery</td>
</tr>
<tr>
<td>Brian Harcourt</td>
<td>Trevor Shoemaker</td>
</tr>
<tr>
<td>Terri Hyde</td>
<td>Julie Villanueva</td>
</tr>
<tr>
<td>Rita Helfand</td>
<td></td>
</tr>
<tr>
<td>Yon Yu</td>
<td></td>
</tr>
</tbody>
</table>
For more information, contact CDC
1-800-CDC-INFO (232-4636)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Vote
Language for Vote

Pre-exposure vaccination with rVSVΔG-ZEBOV-GP vaccine is recommended for adults 18 years of age or older in the U.S. population who are at potential risk of exposure to Ebola virus (species *Zaire ebolavirus*) and:

- Are responding to an outbreak of Ebola virus disease; or
- Work as healthcare personnel\(^1\) at federally-designated Ebola Treatment Centers in the United States; or
- Work as laboratorians or other staff at biosafety-level 4 facilities in the United States